Table 2. Least squares mean reduction in SBP/DBP (mm Hg) from baseline to week 8 (analysis of covariance) in high-risk and non-high-risk individuals treated with nifedipine GITS (N20, 30, 60) and/or candesartan cilexetil (C4, 8, 16, 32) or placebo (efficacy analysis set).
| Treatment group |
Renal impairment of any grade (baseline eGFR<90 ml min−1) |
T2DM |
Hypercholesterolaemia (total cholesterol>240 mg dl−1) |
CV risk factor(s) (T2DM or BMI⩾30 kg m−2 or LDL⩾130 mg dl−1) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes (N=422) | No (N=940) | Yes (N=202) | No (N=1160) | >240 (N=206) | 200–240 (N=450) | <200 (N=704) | 1–3 (N=971) | 1–2 (N=943) | 1 (N=669) | None (N=391) | |
| Placebo | −3.6/−6.8 | −5.7/−6.3 | −11.3/−6.9 | −4.9/−6.2 | −1.4/−8.1 | −4.4/−7.4 | −6.6/−5.8 | −6.2/−7.0 | −6.4/−7.2 | −5.7/−6.3 | 1.2/−3.1 |
| C4 | −6.2/−7.6 | −12.8/−9.7 | −15.7/−10.8 | −11.7/−8.7 | −12.9/−8.5 | −11.5/−8.1 | −11.5/−10.1 | −12.9/−8.8 | −13.0/−8.9 | −10.8/−8.6 | −7.0/−9.5 |
| C8 | −9.0/−9.1 | −14.8/−10.7 | −13.8/−9.4 | −14.1/−10.5 | −19.5/−13.0 | −13.2/−10.9 | −11.7/−9.9 | −13.6/−10.0 | −13.5/−10.1 | −12.3/−10.4 | −10.6/−11.0 |
| C16 | −17.5/−11.1 | −12.6/−8.0 | −14.2/−8.8 | −14.0/−9.1 | −13.8/−10.7 | −12.8/−8.7 | −13.4/−9.7 | −10.9/−7.9 | −10.9/−8.0 | −9.8/−8.2 | −16.3/−10.8 |
| C32 | −15.4/−14.7 | −16.6/−11.4 | −14.0/−10.1 | −17.3/−12.7 | −10.7/−11.4 | −17.8/−12.6 | −16.9/−13.3 | −15.5/−11.5 | −15.5/−11.8 | −15.5/−12.3 | −16.8/−14.8 |
| N20 | −15.2/−13.0 | −11.1/−8.4 | −15.8/−12.6 | −12.0/−9.2 | −14.9/−10.2 | −11.8/−11.6 | −10.9/−8.8 | −11.7/−9.4 | −11.7/−9.3 | −11.2/−8.9 | −10.1/−9.5 |
| N30 | −14.1/−11.0 | −12.6/−9.2 | −19.0/−9.6 | −13.1/−9.7 | −10.7/−11.7 | −14.6/−10.4 | −13.3/−9.3 | −14.5/−10.2 | −14.7/−10.5 | −14.9/−10.4 | −8.2/−7.8 |
| N60 | −16.3/−14.3 | −17.7/−10.3 | −19.5/−12.6 | −16.9/−11.4 | −14.9/−8.1 | −14.7/−9.9 | −18.2/−14.3 | −16.3/−11.3 | −16.4/−11.9 | −16.7/−12.7 | −15.8/−12.0 |
| N20C4 | −19.2/−16.2 | −18.6/−11.8 | −12.4/−15.0 | −19.7/−13.2 | −19.4/−15.5 | −21.4/−15.4 | −17.0/−12.4 | −18.9/−13.9 | −18.9/−14.1 | −17.9/−14.3 | −16.2/−12.0 |
| N20C8 | −21.5/−14.7 | −18.9/−13.8 | −21.0/−15.9 | −20.7/−13.7 | −19.3/−13.5 | −18.0/−12.5 | −21.3/−15.9 | −19.9/−13.5 | −19.6/−13.6 | −19.3/−14.3 | −17.9/−15.2 |
| N20C16 | −19.5/−15.2 | −19.6/−13.9 | −21.5/−17.3 | −21.3/−13.6 | −22.0/−17.1 | −18.3/−12.7 | −21.8/−14.9 | −19.8/−14.1 | −19.7/−14.2 | −20.8/−15.1 | −21.0/−14.1 |
| N30C8 | −20.3/−16.8 | −20.5/−13.4 | −27.0/−18.5 | −20.1/−13.9 | −21.2/−13.7 | −20.1/−13.2 | −19.9/−15.8 | −21.8/−14.3 | −21.6/−14.4 | −21.6/−14.4 | −14.6/−14.3 |
| N30C16 | −22.3/−15.8 | −17.3/−12.8 | −23.3/−11.4 | −19.7/−14.3 | −16.6/−13.6 | −19.3/−14.8 | −19.7/−13.4 | −18.0/−13.4 | −17.7/−13.9 | −17.7/−14.4 | −21.4/−14.6 |
| N30C32 | −22.9/−17.5 | −19.9/−14.6 | −29.0/−17.8 | −21.7/−15.5 | −21.5/−17.1 | −18.6/−15.0 | −24.2/−16.7 | −21.2/−15.3 | −21.3/−15.4 | −19.8/−16.0 | −21.2/−16.2 |
| N60C16 | −17.4/−16.1 | −23.1/−15.6 | −17.8/−14.0 | −23.4/−15.9 | −18.8/−13.7 | −20.4/−15.6 | −22.8/−16.8 | −20.5/−14.5 | −19.8/−14.3 | −19.1/−14.5 | −22.8/−18.7 |
| N60C32 | −29.4/−19.3 | −22.0/−15.0 | −22.0/−14.9 | −24.4/−16.4 | −21.7/−16.7 | −22.9/−16.6 | −24.3/−16.2 | −22.0/−15.0 | −21.9/−15.1 | −21.6/−15.4 | −25.0/−18.0 |
Abbreviations: BMI, body mass index; C, candesartan cilexetil; CV, cardiovascular; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; N, nifedipine GITS; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.